Business Description
Celldex Therapeutics Inc
NAICS : 325413
SIC : 2835
ISIN : US15117B2025
Description
Celldex Therapeutics Inc is a biopharmaceutical company. It is focused on the development and commercialization of several immunotherapy technologies and other cancer-targeting biologics. The company is also engaged in clinical trials for products targeting breast cancer, metastatic melanoma, lung cancer, solid tumors, and ovarian cancer. Its pipeline products are Varlilumab, CDX-301, CDX-1140,CDX-0159/Anti-KIT Program, and CDX-527.
Financial Strength
8/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Cash-To-Debt | 244.9 | |||||
| Equity-to-Asset | 0.96 | |||||
| Debt-to-EBITDA | -0.02 | |||||
| Interest Coverage | N/A |
N/A
|
N/A
| |||
| Piotroski F-Score | 3/9 | |||||
| Altman Z-Score | 27.22 | |||||
| Beneish M-Score | -0.93 | |||||
| WACC vs ROIC | ||||||
Growth Rank
2/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Revenue Growth Rate | -17.2 | |||||
| 3-Year EBITDA Growth Rate | -23.1 | |||||
| 3-Year EPS without NRI Growth Rate | -21.3 | |||||
| 3-Year FCF Growth Rate | -16.7 | |||||
| 3-Year Book Growth Rate | 13.3 | |||||
| Future 3-5Y EPS without NRI Growth Rate | -11.04 | |||||
| Future 3-5Y Total Revenue Growth Rate | -20.88 |
Momentum Rank
5/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 5-Day RSI | 62.91 | |||||
| 9-Day RSI | 58.01 | |||||
| 14-Day RSI | 53.18 | |||||
| 6-1 Month Momentum % | -20.37 | |||||
| 12-1 Month Momentum % | 1.57 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Current Ratio | 24.27 | |||||
| Quick Ratio | 24.27 | |||||
| Cash Ratio | 23.56 | |||||
| Days Sales Outstanding | 58.08 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Average Share Buyback Ratio | -12.2 | |||||
| Shareholder Yield % | -23.7 |
Profitability Rank
1/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Operating Margin % | -1745.97 | |||||
| Net Margin % | -1544.48 | |||||
| FCF Margin % | -1599.44 | |||||
| ROE % | -24.74 | |||||
| ROA % | -23.46 | |||||
| ROIC % | -425.52 | |||||
| ROC (Joel Greenblatt) % | -2591.7 | |||||
| ROCE % | -27.75 |
GF Value Rank
8/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| PS Ratio | 163.33 | |||||
| PB Ratio | 2.32 | |||||
| Price-to-Tangible-Book | 2.4 | |||||
| EV-to-EBIT | -6.13 | |||||
| EV-to-Forward-EBIT | -4.35 | |||||
| EV-to-EBITDA | -6.24 | |||||
| EV-to-Forward-EBITDA | -4.35 | |||||
| EV-to-Revenue | 107.01 | |||||
| EV-to-Forward-Revenue | 197.7 | |||||
| EV-to-FCF | -6.69 | |||||
| Price-to-Median-PS-Value | 1.8 | |||||
| Price-to-Net-Current-Asset-Value | 2.46 | |||||
| Price-to-Net-Cash | 2.53 | |||||
| Earnings Yield (Greenblatt) % | -16.31 | |||||
| FCF Yield % | -8.77 |
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsPeter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Celldex Therapeutics Inc Executives
DetailsAnalyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil €) | 9.128 | ||
| EPS (TTM) (€) | -2.364 | ||
| Beta | 1.54 | ||
| Volatility % | 76.03 | ||
| 14-Day RSI | 53.18 | ||
| 14-Day ATR (€) | 0.8152 | ||
| 20-Day SMA (€) | 24.57 | ||
| 12-1 Month Momentum % | 1.57 | ||
| 52-Week Range (€) | 21.8 - 47.8 | ||
| Shares Outstanding (Mil) | 66.34 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 3 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Celldex Therapeutics Inc Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Celldex Therapeutics Inc Stock Events
| Event | Date | Price(€) | ||
|---|---|---|---|---|
| No Event Data | ||||
Celldex Therapeutics Inc Frequently Asked Questions
What is Celldex Therapeutics Inc(FRA:TCE2)'s stock price today?
The current price of FRA:TCE2 is €26.20. The 52 week high of FRA:TCE2 is €47.80 and 52 week low is €21.80.
When is next earnings date of Celldex Therapeutics Inc(FRA:TCE2)?
The next earnings date of Celldex Therapeutics Inc(FRA:TCE2) is 2025-02-26 Est..
Does Celldex Therapeutics Inc(FRA:TCE2) pay dividends? If so, how much?
Celldex Therapeutics Inc(FRA:TCE2) does not pay dividend.
Press Release
| Subject | Date | |||
|---|---|---|---|---|
| No Press Release | ||||
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers